Expertise in
6
conditions

Rika Sakai

Yokohama, JP 
Expertise in
6
conditions
Yokohama, JP 

Overview

Rika Sakai practices practicing medicine in Yokohama, Japan.

Ms. Sakai is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 92 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Yokohama, Japan
Other Locations
Kanagawa, Japan
Shinjuku, 1698555, Japan
Tokyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3

92 Total Publications

Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit.
Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit.
Journal: Histopathology
Published: October 02, 2025

Frequently Asked Questions about Rika Sakai

Is Rika Sakai a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Rika Sakai is classified as an Distinguished expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rika Sakai participate in research or clinical trials?

Yes. Rika Sakai has published 92 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Rika Sakai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sakai's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile